Open AccessPhase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer
Author(s) -
David Kerr,
G. J. S. Rustin,
Stanley B. Kaye,
Peter Selby,
Norman M. Bleehen,
Peter Harper,
MH Brampton
Publication year - 1995
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/bjc.1995.498
Subject(s) - medicine , colorectal cancer , ovarian cancer , bolus (digestion) , oncology , phases of clinical research , cancer , clinical trial , urology
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.